Saturday 24 May, 2025 12:12 AM
Site map | Locate Us | Login
   Kirloskar Inds gains after Q4 PAT climbs 95% QoQ to Rs 47 cr    Shilpa Medicare zooms as arm partners with Orion Corporation    AIA Engineering gains after Q4 PAT rises 10% QoQ to Rs 285 crore    Alembic Pharma receives USFDA nod for Amlodipine and Atorvastatin Tablets    Bharti Airtel Ltd Partly Paidup leads losers in 'A' group    Dhabriya Polywood soars as Q4 PAT jumps 32% YoY to Rs 5 crore    Devyani Intl Q4 net loss widens to Rs 15 cr    Premier Explosives Ltd leads losers in 'B' group    Premier Explosives drops after weak Q4 numbers    Greenpanel Inds Q4 PAT falls 1% YoY to Rs 29 crore    Volumes spurt at Honasa Consumer Ltd counter    BEML gains as Q4 PAT jumps 12% YoY to Rs 288 cr    Healthcare shares slide    Sun Pharma drops after Q4 PAT slides 19% YoY to Rs 2,1450 cr    Mankind Pharma Ltd slips for fifth straight session 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Alembic Pharma receives USFDA nod for Amlodipine and Atorvastatin Tablets
23-May-25   15:08 Hrs IST

Amlodipine and Atorvastatin tablets are a combination medication used to treat high blood pressure (hypertension) and high cholesterol (hyperlipidemia).

The approved product is therapeutically equivalent to the reference listed drug, Caduet Tablets, marketed by Pharmacia and Upjohn Co. LLC.

The company now has a cumulative total of 223 ANDA approvals from the USFDA, including 199 final approvals and 24 tentative approvals.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.

The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.

The counter shed 0.13% to Rs 971.25 on the BSE.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 41056129
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited